A series of new aporphine analogues were synthesized and pharmacologically evaluated. 11-Allyloxy-(17), 11-propargyloxy-(20), and dihydrofuro-(19) aporphines displayed the highest affinity at the 5-HT(1A) receptor with K(i) values of 12.0, 14.0, and 6.7 nM, respectively. The high binding potential of the diastereomeric mixture of aporphine 19 was found residing in the cis-diastereomer (cis-19). [(35)S]GTP gamma S function assays on 5-HT(1A) receptor indicated that aporphines 17 and 20 were partial agonists, while trans-19 behaved as a high efficacy full antagonist and cis-19 was a full agonist. The agonistic property of cis-19 at the 5-HT(1A) receptor was further confirmed in vitro and in vivo. This compound may be useful as a potential treatment for anxiety.
3‐methyl‐6‐chloro‐7,8‐hydroxy‐1‐(3‐methylphenyl)‐2,3,4,5‐tetrahydro‐1H‐3‐benzazepine (SKF83959), a selective agonist for the putative phosphatidylinositol (PI)‐linked dopamine receptor (DAR), has been shown to possess potent anti‐Parkinson disease effects but produces less dyskinesia and motor fluctuation that are frequently observed in Parkinson disease drug therapies. The present study was designed to detect the neuroprotection of SKF83959 and its potential mechanism for the effect in cultured rat cortical cells. The presence of SKF83959 with a dose range of 0.1–30 μmol/L improved H2O2‐reduced cell viability in a dose‐dependent manner. The anti‐apoptotic action of SKF83959 was partially abolished by pre‐application of the D1 antagonist SCH23390 (30 μmol/L) and the PI 3‐kinase (PI 3‐K) inhibitor LY294002 but not by the MEK1/2 inhibitor PD98059 (30 μmol/L). Moreover, SKF83959 treatment significantly inhibited H2O2‐activated glycogen synthase kinase‐3β (GSK‐3β) which was associated with the drug’s neuroprotective effect, but this inhibition was attenuated by SCH23390 and a selective PI 3‐K inhibitor. Moreover, the application of either SKF83959 or a pharmacological inhibitor of GSK‐3β attenuated the inhibition by H2O2 on the expression of inducible NO synthase and production of NO. This indicates that D1‐like receptor, presumably PI‐linked D1 receptor, ‐mediated alteration of PI 3‐K/Akt/GSK‐3β pathway is involved in the neuroprotection by SKF83959. In addition, SKF83959 also effectively decreased the level of the lipid peroxidation and increased the activity of GSH‐peroxidase altered by H2O2. These results suggest that SKF83959 exerts its neuroprotective effect through both receptor‐dependent and independent mechanisms: Inhibition of GSK‐3β and consequently increasing the expression of inducible NO synthase via putative PI‐linked DAR; and its anti‐oxidative activity which is independent of DAR.
The present study aims to define the role of postsynaptic density (PSD)-95 in the regulation of dopamine (DA) receptor function. We found that PSD-95 physically associates with either D1 or D2 DA receptors in co-transfected HEK-293 cells. Stimulation of DA receptors altered the association between D1 receptor and PSD-95 in a time-dependent manner. Functional assays indicated that PSD-95 co-expression did not affect D1 receptor-stimulated cAMP production, Gs-protein activation or receptor desensitization. However, PSD-95 accelerated the recovery of internalized membrane receptors by promoting receptor recycling, thus resulting in enhanced resensitization of internalized D1 receptors. Our results provide a novel mechanism for regulating DA receptor recycling that may play an important role in postsynaptic DA functional modulation and synaptic neuroplasticity.
The paucity of selective agonists for TWIK-related acid-sensitive K+ 3 (TASK-3) channel, a member of two-pore domain K+ (K2P) channels, has contributed to our limited understanding of its biological functions. By targeting a druggable transmembrane cavity using a structure-based drug design approach, we discovered a biguanide compound, CHET3, as a highly selective allosteric activator for TASK-3–containing K2P channels, including TASK-3 homomers and TASK-3/TASK-1 heteromers. CHET3 displayed potent analgesic effects in vivo in a variety of acute and chronic pain models in rodents that could be abolished pharmacologically or by genetic ablation of TASK-3. We further found that TASK-3–containing channels anatomically define a unique population of small-sized, transient receptor potential cation channel subfamily M member 8 (TRPM8)–, transient receptor potential cation channel subfamily V member 1 (TRPV1)–, or tyrosine hydroxylase (TH)–positive nociceptive sensory neurons and functionally regulate their membrane excitability, supporting CHET3 analgesic effects in thermal hyperalgesia and mechanical allodynia under chronic pain. Overall, our proof-of-concept study reveals TASK-3–containing K2P channels as a druggable target for treating pain.
TWIK-related
K+ (TREK) channels are potential analgesic
targets. However, selective activators for TREK with both defined
action mechanism and analgesic ability for chronic pain have been
lacking. Here, we report (1S,3R)-3-((4-(6-methylbenzo[d]thiazol-2-yl)phenyl)carbamoyl)cyclopentane-1-carboxylic
acid (C3001a), a selective activator for TREK, against other two-pore
domain K+ (K2P) channels. C3001a binds to the cryptic binding
site formed by P1 and TM4 in TREK-1, as suggested by computational
modeling and experimental analysis. Furthermore, we identify the carboxyl
group of C3001a as a structural determinant for binding to TREK-1/2
and the key residue that defines the subtype selectivity of C3001a.
C3001a targets TREK channels in the peripheral nervous system to reduce
the excitability of nociceptive neurons. In neuropathic pain, C3001a
alleviated spontaneous pain and cold hyperalgesia. In a mouse model
of acute pancreatitis, C3001a alleviated mechanical allodynia and
inflammation. Together, C3001a represents a lead compound which could
advance the rational design of peripherally acting analgesics targeting
K2P channels without opioid-like adverse effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.